Inclusion Criteria:

          1. Signed written informed consent.

          2. Patient is at least 18 years-of-age at the time of signature of the informed consent
             form (ICF).

          3. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0
             or 1.

          4. Patient must have a confirmed diagnosis of locally advanced, unresectable and/or
             metastatic solid tumor(s), have failed standard treatment, or refuse standard
             treatment, or have a tumor for which no therapy of proven efficacy exists, or a tumor
             that is not amenable to standard therapies.

          5. Patient has measurable disease on imaging based or non-measurable disease.

          6. Patient will be requested to provide a fresh pre-treatment biopsy specimen, otherwise
             they are required to provide an archival diagnostic tumor sample that is <1 year old.

          7. Patient has a life expectancy ≥3 months according to the Investigator's judgment.

          8. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at
             screening within 72 hours of first dose of MTB-9655. In addition, WOCBP are required
             to use two forms of acceptable contraception.

          9. Male patients with WOCBP partners must agree to use highly effective contraceptive
             measures throughout the study starting with screening visit through 120 days after the
             last dose.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from study entry:

          1. Treatment with any of the following:

               -  Any systemic anti-cancer chemotherapy, small molecule, biologic, or hormonal
                  agent from a previous treatment regimen or clinical study within 28 days or 5
                  half-lives (whichever is shorter) prior to the first dose of study drug. At least
                  10 days must have elapsed between the last dose of such agent and the first dose
                  of study drug.

               -  Wide-field radiotherapy administered ≤28 days or limited field radiation for
                  palliation ≤7 days prior to starting study drug.

               -  Major surgery(excluding placement of vascular access) within 3 weeks of first
                  dose of study drug.

               -  Prior treatment with other drug with the same mechanism of action (directed to
                  ACSS2).

               -  Receiving systemic corticosteroid therapy 1 week prior to the first dose of study
                  drug or receiving any other form of systemic immunosuppressive medication for
                  medically significant acute or chronic conditions.

          2. Persistent toxicity of National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy.

          3. Central nervous system tumor, metastasis(es), and/or carcinomatous meningitis
             identified either on the baseline brain imaging obtained during the screening period
             or identified prior to consent.

          4. Active infection requiring treatment.

          5. Out-of-range laboratory values defined as:

               -  Absolute neutrophil count (ANC) <1.5 × 10^9/L

               -  Hemoglobin <9 g/dL

               -  Platelets <100 × 10^9/L)

               -  Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) >2.5 × the
                  upper limit of normal (ULN) or ≥5 × ULN with liver involvement

               -  Total bilirubin >1.5 × ULN

               -  Serum creatinine >1.5 × ULN or creatinine clearance (CrCl≤60mL/min, measured or
                  calculated using the Cockcroft-Gault Method

               -  International Normalized Ratio (INR) or prothrombin time (PT) >1.5 × ULN and
                  activated partial thromboplastin time (aPTT) >1.5 × ULN (unless patient is
                  receiving anticoagulant therapy)

          6. Inability to swallow oral medications or presence of active gastrointestinal disease
             or other condition that will interfere significantly with the absorption,
             distribution, metabolism, or excretion of MTB-9655 (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea Grade ≥2, malabsorption syndrome).

          7. Any of the following cardiac criteria:

               -  Known history of marked prolongation of QT/corrected QT(QT/QTc) interval.

               -  Clinically significant cardiovascular disease, including cerebral vascular
                  accident/stroke or myocardial infarction within 6 months of enrollment, unstable
                  angina, congestive heart failure,or serious uncontrolled cardiac arrhythmia
                  requiring medication.

               -  History of additional risk factors for Torsade de Pointes (including heart
                  failure, hypokalemia, family history of long QT syndrome, and use of concomitant
                  medications that prolong the QT/QTc interval.

               -  Patients with a left ventricular ejection fraction (LVEF) <50%.

          8. History of concomitant malignancy with recurrence <3 year from enrolment.

          9. Expected to require any other form of systemic or localized antineoplastic therapy
             while on trial.

         10. Significant liver cirrhosis defined as Child-Pugh Class B or C.

         11. History of hemolytic disorders.

         12. Active infection with human immunodeficiency virus (HIV).

         13. History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the patient's participation
             for the full duration of the study, or is not in the best interest of the patient to
             participate, in the opinion of the treating Investigator.

         14. Pregnant or breastfeeding.